Abstract Number: 0134 • ACR Convergence 2021
Systemic Lupus Erythematosus Is a Risk Factor for Mortality in Older Patients with Early-Stage Breast Cancer
Background/Purpose: Women with systemic lupus erythematosus (SLE) who develop breast cancer (BC), may receive different therapies (e.g. radiation) than women with BC who do not…Abstract Number: 0333 • ACR Convergence 2021
Validation of the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria for Systemic Lupus Erythematosus (SLE) in Hong Kong Chinese
Background/Purpose: To validate the 2019 EULAR/ACR classification criteria for SLE in Hong Kong Chinese patients and compare its performance with the 2012 Systemic Lupus International…Abstract Number: 0351 • ACR Convergence 2021
Gene Signature Fingerprints Divide SLE Patients in Subgroups with Similar Biological Disease Profiles: A Multicenter Longitudinal Study
Background/Purpose: Clinical phenotyping and predicting treatment responses in Systemic Lupus Erythematosus (SLE) patients is challenging. Extensive blood transcriptional profiling has identified various gene modules that…Abstract Number: 0535 • ACR Convergence 2021
Therapeutic Efficacy of a Biomimetic ALXR Agonist in Murine Systemic Lupus Erythematosus (SLE)
Background/Purpose: Neutrophils are key initiators and promoters of autoimmunity, including SLE, via the elaboration of neutrophil extracellular traps (NETs). We tested the efficacy of the…Abstract Number: 0626 • ACR Convergence 2021
Does Higher Quality of Care in SLE Translate to Better Patient Outcomes?
Background/Purpose: Quality of care (QOC) as measured by quality indicators (QIs) decreases damage accrual in SLE long term. We aimed to assess if high QOC…Abstract Number: 0857 • ACR Convergence 2021
Association of Telomere Length with Phenotypic Frailty in Systemic Lupus Erythematosus
Background/Purpose: Frailty is a novel risk factor for adverse health outcomes in systemic lupus erythematosus (SLE). Although frailly is conceptualized as “accelerated aging,” whether the…Abstract Number: 0874 • ACR Convergence 2021
Serum Galectin-9 and CXCL-10 but Not Their Urinary Levels Reflect Lupus Activity
Background/Purpose: SLE is characterized by increased type I IFN signature in the blood and immune cells. Traditionally, type I IFN signature is measured by gene…Abstract Number: 0892 • ACR Convergence 2021
Screening for Cognitive Impairment with the Automated Neuropsychological Assessment Metrics in Patients with Systemic Lupus Erythematosus
Background/Purpose: The American College of Rheumatology Neuropsychological Battery (ACR-NB) is the standard screening test for cognitive impairment (CI) in systemic lupus erythematosus (SLE). While the…Abstract Number: 1032 • ACR Convergence 2021
Causes of Death Among Populations with Systemic Lupus Erythematosus by Race and Ethnicity
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease with manifestations that vary widely in severity. Data indicate that minority populations are at higher…Abstract Number: 1178 • ACR Convergence 2021
Implementation of a Dermatologic Manifestations of Connective Tissue Disease Learning Module Including All Skin Tones and Social Determinants of Health for Medical Students: A Pilot Study
Background/Purpose: There is a dearth of resources for medical students on identifying skin findings of autoimmune disorders in skin of color. Considering how several rheumatologic…Abstract Number: 1271 • ACR Convergence 2021
Healthcare Resource Utilization and Costs Associated with Systemic Lupus Erythematosus After Diagnosis of End-Stage Kidney Disease: Evidence from Two United States Databases
Background/Purpose: Approximately 40% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN), of whom up to 20% may progress to end-stage kidney disease…Abstract Number: 1287 • ACR Convergence 2021
Association of Limited Health Literacy with Patient-Provider Communication in Systemic Lupus Erythematosus
Background/Purpose: Low health literacy is common among US adults, including patients with SLE, and is associated with higher disease activity and worse patient-reported outcomes. The…Abstract Number: 1386 • ACR Convergence 2021
Measurement of TIMP-1 in Pulmonary Vessels May Be a Novel Marker of Reflecting mPAP in CTD-PH
Background/Purpose: CTD is a disease with immune abnormalities which could alter normal cytokine profile. CTD-PH has a different pathogenesis from that of iPAH, and immunosuppressive…Abstract Number: 1466 • ACR Convergence 2021
Increased Adverse Maternal Postpartum Outcomes in Systemic Lupus Erythematosus Pregnancies Compared to Controls
Background/Purpose: Studies show increased risks of adverse pregnancy outcomes in SLE patients. Few studies have investigated postpartum outcomes in these patients. Using a large, de-identified…Abstract Number: 1498 • ACR Convergence 2021
Platelet Secreted LGALS3BP Induces a Pro-inflammatory Phenotype in Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex chronic heterogeneous autoimmune disease, which increases the risk of atherothrombosis. In addition to their well described role…
- « Previous Page
- 1
- …
- 90
- 91
- 92
- 93
- 94
- …
- 150
- Next Page »